939 related articles for article (PubMed ID: 23334437)
1. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
3. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
[TBL] [Abstract][Full Text] [Related]
4. The clinical performance of APTIMA human papillomavirus and Hybrid Capture 2 assays in the triage of lesser abnormal cervical cytologies.
Guo Y; You K; Geng L; Qiao J
J Gynecol Oncol; 2014 Oct; 25(4):287-92. PubMed ID: 25142625
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: Implications for vaginal self-collection.
Belinson JL; Hu S; Niyazi M; Pretorius RG; Wang H; Wen C; Smith JS; Li J; Taddeo FJ; Burchette RJ; Qiao YL
Int J Cancer; 2010 Sep; 127(5):1151-7. PubMed ID: 20039323
[TBL] [Abstract][Full Text] [Related]
8. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
10. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
[TBL] [Abstract][Full Text] [Related]
12. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
14. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
15. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.
Rebolj M; Bonde J; Preisler S; Ejegod D; Rygaard C; Lynge E
PLoS One; 2016; 11(1):e0147326. PubMed ID: 26789267
[TBL] [Abstract][Full Text] [Related]
16. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial.
Cook DA; Smith LW; Law JH; Mei W; Gondara L; van Niekerk DJ; Ceballos KM; Jang D; Chernesky M; Franco EL; Ogilvie GS; Coldman AJ; Krajden M
J Clin Virol; 2018 Nov; 108():32-37. PubMed ID: 30223252
[TBL] [Abstract][Full Text] [Related]
17. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
[TBL] [Abstract][Full Text] [Related]
18. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology.
Rebolj M; Lynge E; Ejegod D; Preisler S; Rygaard C; Bonde J
Gynecol Oncol; 2014 Dec; 135(3):474-80. PubMed ID: 25449563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]